Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies

Documenti analoghi

• Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?
  di: Santino Caserta, et al.
  Pubblicazione: (2025)
• APE1 Attenuates ALK Tyrosine Kinase Inhibitors Sensitivity in NPM1‐ALK Positive Anaplastic Large Cell Lymphoma
  di: Zheng Liu, et al.
  Pubblicazione: (2025)
• Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Bruton's Tyrosine Kinase Inhibitors: Real‐World Impact of Cardiovascular Adverse Events
  di: Mavis Obeng‐Kusi, et al.
  Pubblicazione: (2025)
• Rapid HHV ‐6 Clearance Following Preemptive Short‐Course Foscarnet in Allogeneic Stem Cell Transplant Recipients
  di: Piyatida Chumnumsiriwath, et al.
  Pubblicazione: (2026)
• A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi‐Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De‐Differentiated Chondrosarcoma
  di: Matthew Youssef, et al.
  Pubblicazione: (2026)